Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ranibizumab retinal function study in wet age-related macular degeneration
2010-021777-37Phase 4Completed
- Sponsor
- Universitätsklinikum Schleswig-Holstein
- Start
- Aug 2010
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of ranibizumab in exudative macular degeneration, sponsored by Universitätsklinikum Schleswig-Holstein. Primary endpoints: Change in macular retinal function by multifocal electroretinography at 12 months and Change in macular retinal function by microperimetry at 12 months. Started Aug 2010; status: completed.
02
Drugs
ranibizumab
03
Conditions
exudative macular degeneration
Beyond the preview
Go deeper on 2010-021777-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-021777-37.